131 related articles for article (PubMed ID: 15857110)
21. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity.
He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Bakshi RK; Dellureficio JP; Hong Q; Weinberg DH; Macneil T; Tang R; Strack AM; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Fong TM; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4399-405. PubMed ID: 20598882
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationships of beta-MSH derived melanocortin-4 receptor peptide agonists.
Yan LZ; Hsiung HM; Heiman ML; Gadski RA; Emmerson PJ; Hertel J; Flora D; Edwards P; Smiley D; Zhang L; Husain S; Kahl SD; DiMarchi RD; Mayer JP
Curr Top Med Chem; 2007; 7(11):1052-67. PubMed ID: 17584126
[TBL] [Abstract][Full Text] [Related]
24. Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
Zhu C; Hansen AR; Bateman T; Chen Z; Holt TG; Hubert JA; Karanam BV; Lee SJ; Pan J; Qian S; Reddy VB; Reitman ML; Strack AM; Tong V; Weingarth DT; Wolff MS; MacNeil DJ; Weber AE; Duffy JL; Edmondson SD
Bioorg Med Chem Lett; 2008 Aug; 18(15):4393-6. PubMed ID: 18614364
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I
Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206
[TBL] [Abstract][Full Text] [Related]
26. Design of cyclic peptides with agonist activity at melanocortin receptor-4.
Odagami T; Tsuda Y; Kogami Y; Kouji H; Okada Y
Bioorg Med Chem Lett; 2006 Jul; 16(14):3723-6. PubMed ID: 16678415
[TBL] [Abstract][Full Text] [Related]
27. The effect of assay formats on the estimation of melanocortin agonist affinity and efficacy using the operation model of agonism.
Simon S; Young TJ; Nickolls SA
Eur J Pharmacol; 2009 Aug; 615(1-3):33-9. PubMed ID: 19446549
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship of linear tetrapeptides Tic-DPhe-Arg-Trp-NH2 at the human melanocortin-4 receptor and effects on feeding behaviors in rat.
Ye Z; MacNeil T; Weinberg DH; Kalyani RN; Tang R; Strack AM; Murphy BA; Mosley RT; Euan MacIntyre D; Van der Ploeg LH; Patchett AA; Wyvratt MJ; Nargund RP
Peptides; 2005 Oct; 26(10):2017-25. PubMed ID: 15993513
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
[TBL] [Abstract][Full Text] [Related]
30. Beta-MSH inhibits brain inflammation via MC(3)/(4) receptors and impaired NF-kappaB signaling.
Muceniece R; Zvejniece L; Kirjanova O; Liepinsh E; Krigere L; Vilskersts R; Baumane L; Gordjusina V; Kalvinsh I; Wikberg JE; Dambrova M
J Neuroimmunol; 2005 Dec; 169(1-2):13-9. PubMed ID: 16154641
[TBL] [Abstract][Full Text] [Related]
31. Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for receptor activation.
Hogan K; Peluso S; Gould S; Parsons I; Ryan D; Wu L; Visiers I
J Med Chem; 2006 Feb; 49(3):911-22. PubMed ID: 16451057
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor.
Chen C; Jiang W; Tran JA; Tucci FC; Fleck BA; Markison S; Wen J; Madan A; Hoare SR; Foster AC; Marinkovic D; Chen CW; Arellano M; Saunders J
Bioorg Med Chem Lett; 2008 Jan; 18(1):129-36. PubMed ID: 18032040
[TBL] [Abstract][Full Text] [Related]
33. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.
Xin Z; Serby MD; Zhao H; Kosogof C; Szczepankiewicz BG; Liu M; Liu B; Hutchins CW; Sarris KA; Hoff ED; Falls HD; Lin CW; Ogiela CA; Collins CA; Brune ME; Bush EN; Droz BA; Fey TA; Knourek-Segel VE; Shapiro R; Jacobson PB; Beno DW; Turner TM; Sham HL; Liu G
J Med Chem; 2006 Jul; 49(15):4459-69. PubMed ID: 16854051
[TBL] [Abstract][Full Text] [Related]
34. Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist.
Ye Z; Guo L; Barakat KJ; Pollard PG; Palucki BL; Sebhat IK; Bakshi RK; Tang R; Kalyani RN; Vongs A; Chen AS; Chen HY; Rosenblum CI; MacNeil T; Weinberg DH; Peng Q; Tamvakopoulos C; Miller RR; Stearns RA; Cashen DE; Martin WJ; Metzger JM; Strack AM; MacIntyre DE; Van der Ploeg LH; Patchett AA; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2005 Aug; 15(15):3501-5. PubMed ID: 15982875
[TBL] [Abstract][Full Text] [Related]
35. Multimeric alpha-MSH has increased efficacy to activate the melanocortin MC4 receptor.
Tiesjema B; Merkestein M; Garner KM; de Krom M; Adan RA
Eur J Pharmacol; 2008 May; 585(1):24-30. PubMed ID: 18378226
[TBL] [Abstract][Full Text] [Related]
36. Potent and selective agonists of human melanocortin receptor 5: cyclic analogues of alpha-melanocyte-stimulating hormone.
Bednarek MA; MacNeil T; Tang R; Fong TM; Cabello MA; Maroto M; Teran A
J Med Chem; 2007 May; 50(10):2520-6. PubMed ID: 17455928
[TBL] [Abstract][Full Text] [Related]
37. Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
Semple G; Tran TA; Kramer B; Hsu D; Han S; Choi J; Vallar P; Casper MD; Zou N; Hauser EK; Thomsen W; Whelan K; Sengupta D; Morgan M; Sekiguchi Y; Kanuma K; Chaki S; Grottick AJ
Bioorg Med Chem Lett; 2009 Nov; 19(21):6166-71. PubMed ID: 19773162
[TBL] [Abstract][Full Text] [Related]
38. Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.
Wacker DA; Varnes JG; Malmstrom SE; Cao X; Hung CP; Ung T; Wu G; Zhang G; Zuvich E; Thomas MA; Keim WJ; Cullen MJ; Rohrbach KW; Qu Q; Narayanan R; Rossi K; Janovitz E; Lehman-McKeeman L; Malley MF; Devenny J; Pelleymounter MA; Miller KJ; Robl JA
J Med Chem; 2007 Mar; 50(6):1365-79. PubMed ID: 17315987
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
40. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
